You are here

Development of the first thermolytic to suppress shivering and seizure

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL135964-01A1
Agency Tracking Number: R41HL135964
Amount: $457,306.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA19-029
Timeline
Solicitation Year: 2017
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-09-01
Award End Date (Contract End Date): 2020-08-31
Small Business Information
970 WATER THRUSH DR, Fairbanks, AK, 99712-1451
DUNS: 079899927
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 KELLY DREW
 (907) 474-7190
 kdrew@alaska.edu
Business Contact
 KELLY DREW
Phone: (907) 388-5311
Email: becoolpharma@gmail.com
Research Institution
 UNIVERSITY OF ALASKA FAIRBANKS
 2145 North Tanana Loop, 008 West Ridge Research Building
FAIRBANKS, AK, 99775-7880
 Nonprofit college or university
Abstract
Summary The temperature management market is expected to reach $billion byyet no pharmaceutical has yet been developed specifically for this marketAadenosineA ARagonists are well known to attenuate seizure and protect the brain from injurybut development of these drugs has been limited by side effects including hypothermiabradycardia and hypotensionInspired by our discoveries thatN cyclohexyl adenosineCHAlowers body temperature and induces hibernation and that cardiovascular side effects of CHA can be reversed with a peripherally acting adenosine receptor antagonistp Sulfophenyl theophyllineSPTwithout affecting body temperaturethe present proposal aims to meet three milestones that will define the market to target for commercializationAimis to meet our first milestone which is to demonstrate that CHASPT attenuates shivering better than state of the art meperidine buspirone in rats cooled toCAimis to meet our second milestone which is to demonstrate CHASPTattenuates seizure better than meperidine buspirone and Aimis to meet our third milestone to demonstrate neuroprotective efficacy of CHASPT at target temperatures ofC andC while showing that CHASPT controls shivering and seizure at both target temperaturesWhen completed we will have necessary preliminary data to define the thermolyticantiseizure and neuroprotective efficacy and side effects of CHASPT relative to the state of the art antishivering medicationThese outcomes will be accomplished through standard methods currently used in the PIandapos s laboratoryThe results will significantly contribute to proving the scientific and technical feasibility of developing CHA combined withSPT as a novel thermolytic and antiseizure medication that will make targeted temperature management accessible to underserved populations and meet market demand to treat post operative shiveringThe proposed work is necessary to justify additional support in Phase II Narrative Post operative shivering is driving market demand for effective anti shivering agentsWe will develop a drug toInhibit shivering andMake targeted temperature management accessible to underserved cardiac arrest patients living in rural and remote locations

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government